Subsidiaries Silence EContact Us>
Silence Therapeutics Silence Therapeutics
▲
170.00p (+0.50p)
Vol: 8025
(15-minute delayed)
View full stock quote


  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi Hub
  • Menu
  • About Us
    • Overview
    • Strategy
    • History
    • Management
    • Board Of Directors
    • Scientific Advisory Board
    • Careers
  • RNAI Platform
    • Overview
    • Delivery Platform
    • RNAi Platform
    • RNA Interference
    • Intellectual Property
    • Publications
    • Glossary
  • Pipeline
    • Overview
    • Pre-Clinical development
  • Collaborations
    • Overview
    • Silence's Strengths
    • Partnerships
    • Partnering Opportunities
  • Investor Relations
    • Overview
    • Press Releases
    • Reports and Disclosures
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Publications
  • RNAi Hub
  • Contact
 

Site Map

Home

About Us

  • Strategy
  • Management
  • Board Of Directors
  • History
  • Scientific Advisory Board

Platform Technologies

  • RNA Interference
  • RNAi Platform
  • Delivery Platform
  • Intellectual Property
  • Publications
  • Glossary

Pipeline

  • Pre-Clinical Development

Collaborations

  • Silence's Strengths
  • Partnerships
  • Partnering Opportunities

Investor Relations

  • Press Releases
  • Reports and Disclosures
  • Analyst Coverage

News & Events

  • Press Releases
  • Events
  • In the News
  • Publications

RNAi Hub

Silence News

  • 18.06.13

    Atu027 update: progression into Phase IIa

  • 12.06.13

    Silence Therapeutics sponsors number one ranked US chess player

  • 03.06.13

    Notice of General Meeting and Annual Report

  • 29.05.13

    Final Results

  • 29.05.13

    Directorate Change

  • 19.09.12Silence Twitter

    Read more on our recent appointment of Michael Khan as Chief Medical Adviser on our Board of Directors via http://t.co/2n06ndLl
    271 days ago

  • 12.09.12Silence Twitter

    Silence Therapeutics was featured in the Daily Mail yesterday, full article via this link http://t.co/ymBzzY1M
    278 days ago



Quick Links

  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi HUB
  • Site Map

Contact

3 Shortlands
Hammersmith
London W6 8DA
United Kingdom


Tel:+44 (0) 333 9880 140
Fax:+44 (0) 795 731 8494
Silence Therapeutics

Copyright © 2013 Silence Therapeutics.
All rights reserved.

Terms of Use
Forward-Looking Statement